Test Price
2,800 AED✅ Home Collection Available
SCN10A Gene Episodic Pain Syndrome Type 2, Familial – Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing with full gene coverage by next‑generation sequencing.
- Premium Logistics: VIP mobile phlebotomy & temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM, ensuring hospital‑grade sample integrity.
- Clinical Guidance: Complimentary telephonic post‑test clinical interpretation with a consultant medical geneticist to correlate results with patient history.
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This next‑generation sequencing (NGS) test analyses the complete coding region of the SCN10A gene, which is responsible for familial episodic pain syndrome type 2 (FEPS2). The assay detects pathogenic single‑nucleotide variants, insertions, deletions, and copy‑number variations across all exons and flanking intronic regions with high analytical sensitivity.
| Feature | Our NGS Test – ISO 9001:2015 | Closest Alternative (Sanger Single‑Exon) |
|---|---|---|
| Precision | 99.9% analytical sensitivity; full gene coverage | ~95%; may miss deep intronic mutations |
| Methodology | NGS with bioinformatic confirmation and variant classification per ACMG guidelines | Sanger sequencing of single exons only |
| Turnaround | 3–4 weeks, dedicated genetic counselling report | 6–8 weeks, often limited interpretation |
Relevant Specialists: Neurologist (primary diagnosing physician), Genetic Counsellor (family pedigree & risk assessment), Medical & PhD Researcher/Molecular Geneticist (variant classification).
Physician Insight & Safety Protocols
“I have reviewed this test’s clinical utility for familial episodic pain syndrome. A positive SCN10A result confirms a molecular diagnosis but must be correlated with the patient’s detailed pain history and physical examination; a negative result does not exclude other pain disorders. Always involve a genetic counsellor to interpret variants of uncertain significance and to discuss familial cascade testing options.”
– Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Exclusion Criteria & ER Red Flags
- Exclusion: Unstable acute pain crisis – test only after medical stabilisation.
- Exclusion: Minors under 18 years without legal guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- ER Red Flag: Sudden severe chest pain, syncope, or autonomic instability after blood draw – seek immediate emergency care.
- ER Red Flag: Signs of anaphylaxis or uncontrolled bleeding at the puncture site.
Patient FAQ & Clinical Guidance
1. What does the SCN10A genetic test detect and how does it help my pain diagnosis?
Snippet: This test identifies mutations in the SCN10A gene causing familial episodic pain syndrome type 2, a rare inherited disorder marked by severe, brief body pain episodes often triggered by cold or mechanical stimuli.
A definitive molecular diagnosis guides targeted management, genetic counselling, and family risk assessment. The NGS method scans the entire coding sequence, ensuring even rare variants are captured and classified according to international standards.
2. How should I prepare for the sample collection and what is included in the 2800 AED price?
Snippet: No fasting is required; you simply need a clinical pain history and attend a 20‑minute genetic counselling session before the blood draw.
The all‑inclusive fee covers the counselling, temperature‑controlled home collection service (8 AM‑11 PM daily), NGS laboratory processing, a comprehensive report with variant interpretation, and a telephonic post‑test explanation with a genetic counsellor.
3. If my result is positive, what does that mean for my family members?
Snippet: A positive SCN10A mutation confirms autosomal dominant inheritance, meaning each child has a 50% chance of inheriting the disorder.
Your genetic counsellor will explain the implications, arrange cascade testing for at‑risk relatives, and discuss reproductive options, all in compliance with UAE PDPL confidentiality and data protection standards.
4. Can this test be performed alongside other genetic panels?
Snippet: Yes, the NGS platform allows simultaneous analysis of additional pain‑related genes, such as SCN9A and SCN11A, in a single workflow.
If you have a broader differential diagnosis, your physician can request an expanded pain‑syndrome panel without requiring additional blood draws, optimising both turnaround time and cost.
5. How do I receive my results and what support is available afterward?
Snippet: Results are delivered via secure digital portal and explained during a telephone consultation with a board‑certified genetic counsellor within 3–4 weeks.
A printed clinical report is also provided for your referring neurologist. Our genetics team remains available for ongoing queries regarding family planning, variant reinterpretation over time, and referral to specialty pain clinics.
UAE Regulatory & Data Privacy Adherence
- Data Protection: All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Governance: Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields ensures secure electronic health records and encrypted data transmission.
- Clinical Safety & Consent: Patient safety and informed consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability, governing all diagnostic procedures and genetic counselling interactions.
- Accreditation: ISO 9001:2015 certification for quality management systems (certificate number INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | SCN10A Gene Episodic Pain Syndrome Type 2, Familial – NGS Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA), extracted DNA, or FTA card |
| Methodology Used | Next‑Generation Sequencing (NGS) with bioinformatic variant confirmation |
| ICD-10-CM Code | G90.8, Z14.8, R52 |
| LOINC Code | 82939-0 |
| DHA Facility License & Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians